Global Myelofibrosis Therapeutics Market 2018-2022
About this market
Myelofibrosis is as Philadelphia chromosome- negative myeloproliferative neoplasm (MPN), a rare mutation. The only FDA approved drug therapy is JAKAVI/JAKAFI (Ruxolitinib). It is a potent oral JAK1/ JAK2 inhibitor used for treating the patients with myelofibrosis. HSCT therapy is also having disadvantages regarding the unavailability of matching donors. Other therapies, including the transfusion and androgen therapy, merely reduce the anemic side effects of myelofibrosis. Thus, among all treatments available at present, none can be considered as an ideal one that can completely help in eradicating the disease. Technavio’s analysts have predicted that the myelofibrosis therapeutics market will register a CAGR of more than 7% by 2022.
Increasing number of companies entering the myelofibrosis segment
Before the launch of JAKAVI/JAKAFI, there were very few companies investing in the R&D of myelofibrosis therapies.
Limited market size as myelofibrosis is a rare disorder
The number of available therapies including the orphan drugs for this disorder is very limited. The treatment options employed by physicians are mostly the off- label drugs that are meant for the treatment of some other condition or the blood transfusion or stem cell transplantation.
For the detailed list of factors that will drive and challenge the growth of the myelofibrosis therapeutics market during the 2018-2022, view our report.
The global myelofibrosis therapeutics market is extremely concentrated. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Technavio Announces the Publication of its Research Report – Global Myelofibrosis Therapeutics Market 2018-2022
Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is the high off- label prescription including hydroxyurea, Immunomodulators and steroids.”
According to the report, one of the major drivers for this market is the increasing number of companies entering the myelofibrosis segment.
Further, the report states that one of the major factors hindering the growth of this market is the undefined etiology and unidentified cause of disease progression.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook